The Peptide EraEvidence, not hypeSearch
Menu

The market map

Four brands. Two molecules.

The single most useful thing to understand about this category: the brand names trace back to just two active molecules. Same molecule, different approved use — that’s the whole decoder ring.

Descriptive only — not a buying guide, not medical advice, and no sourcing or doses.

The molecule graph

Brands map to molecules, not vibes

Semaglutidea GLP-1 receptor agonist
Tirzepatidea dual GLP-1 and GIP receptor agonist

Tap a molecule for the generic-drug hub, or a brand for its control panel.

Brand comparison

BrandMoleculeMakerFDA-approved forSibling brand
OzempicsemaglutideNovo Nordisktype 2 diabetes (and, in adults with type 2 diabetes and heart disease, reducing cardiovascular risk)Wegovy
WegovysemaglutideNovo Nordiskchronic weight management, and reducing cardiovascular risk in adults with obesity or overweight plus established heart diseaseOzempic
MounjarotirzepatideEli Lillytype 2 diabetesZepbound
ZepboundtirzepatideEli Lillychronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesityMounjaro

Approved uses are from each product’s FDA label. “Same molecule, different approved use” is why one drug can have two brand names.

What each brand is approved for

FDA-approved indications by brand
BrandMoleculeType 2 diabetesWeight managementCardiovascular riskObstructive sleep apnea
Ozempicsemaglutide✓—✓*—
Wegovysemaglutide—✓✓*—
Mounjarotirzepatide✓———
Zepboundtirzepatide—✓—✓

✓ FDA-approved · ✓* approved in a defined sub-population (e.g. cardiovascular-risk reduction requires established heart disease). From each product’s FDA label. Not medical advice, not a buying guide.

The two molecules

Read the evidence